News Articles

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford to Investigate the Effects... INGELHEIM, Germany & INDIANAPOLIS, Ind. -Monday, April 16th 2018  

(BUSINESS WIRE) -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in...

Boehringer Ingelheim to invest €65 million in avian vaccines LYON, France -Thursday, April 12th 2018  

(BUSINESS WIRE) -- Six months after inaugurating its new French animal health headquarters in the heart of the Lyon-Gerland Biodistrict, Boehringer Ingelheim has confirmed its allegiance to the region by announcing that it is about to invest a further €65 million in the metropolitan...

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering... INGELHEIM, Germany & NANTES, France -Thursday, April 5th 2018

(BUSINESS WIRE) -- Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist...

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory... INGELHEIM, Germany -Thursday, March 29th 2018  

Results enhance existing evidence base showing Spiolto® Respimat® improves symptom reduction and quality of life over Spiriva® Respimat®2,3,4,5,6 For media excluding the United States of America, Canada and the United Kingdom (BUSINESS WIRE) -- Boehringer Ingelheim today...

Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth... XI’AN, China -Monday, March 26th 2018

(BUSINESS WIRE) -- Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vaccine company targeting foot-and-mouth disease in swine, was launched on March 24th with a groundbreaking ceremony held at the Airport New City in Xi’an, capital city of Shaanxi Province. Meili...

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world... INGELHEIM, Germany -Tuesday, March 20th 2018  

Complete Phase II results from the prospective GLORIATM-AF registry in dabigatran patients presented as a late-breaker at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA)1 Low rates of major bleeding and stroke observed for dabigatran patients1 Long-term...

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial... INGELHEIM, Germany & RIDGEFIELD, Conn. -Monday, March 19th 2018

Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need The designation is based on the Investigational New Drug Application for SSc-ILD and the anticipated efficacy and safety data from the Phase III SENSCIS™...

Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials INGELHEIM, Germany & INDIANAPOLIS, US -Tuesday, March 6th 2018  

  EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure1,2 EMPERIAL is part of the most comprehensive clinical trial programme of an SGLT2 inhibitor in chronic heart...

Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’ INGELHEIM, Germany -Wednesday, February 28th 2018

Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF. Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not...

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than... INGELHEIM, Germany & BOSTON -Wednesday, January 3rd 2018

(BUSINESS WIRE)-- Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in promising early stage start-up companies, focusing on...

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017 RIDGEFIELD, Conn. & INGELHEIM, Germany -Monday, December 11th 2017

(BUSINESS WIRE)-- 2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged...

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if... INGELHEIM, Germany -Wednesday, November 15th 2017  

Dual therapy with dabigatran consistently favourable across key sub-groups in atrial fibrillation patients following PCI with stent placement Benefits shown in sub-group analyses were consistent with overall results of the trial Data presented at AHA Scientific Sessions 2017 reinforce...

New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in... INGELHEIM, Germany -Tuesday, November 14th 2017  

Additional analyses of patients in diverse emergency settings confirm that idarucizumab immediately reverses the anticoagulant effect of dabigatran in patients in emergency settings1,2 Sub-analyses from RE-VERSE AD™, the largest study to investigate a reversal agent for a non-vitamin K...

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases INGELHEIM, Germany & LONDON -Wednesday, November 8th 2017

(BUSINESS WIRE)--Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on...

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo® INGELHEIM, Germany -Monday, November 6th 2017

48-week Phase III data showed Cyltezo® and Humira® have similar efficacy, safety and immunogenicity in people with rheumatoid arthritis1 Patients who switched at week 24 from Humira® to Cyltezo® showed no difference to continuous Humira® usage1 Data will be presented at the American...

Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology... INGELHEIM, Germany & NASHVILLE, Tenn. -Tuesday, October 31st 2017  

(BUSINESS WIRE)--Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim’s oncology...

Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV... INGELHEIM, Germany & INDIANAPOLIS, US -Tuesday, September 12th 2017  

Three sub-analyses of the EMPA-REG OUTCOME® trial in people with type 2 diabetes and established cardiovascular disease* presented at EASD 20171-3 Irrespective of their blood sugar control at study start, participants* taking Jardiance® had a lower risk of cardiovascular death compared to...

Safety and efficacy results from the INJOURNEYTM trial investigating OFEV® (nintedanib) with add-on... INGELHEIM, Germany -Monday, September 11th 2017

Data from this 12-week study show that the safety and tolerability profile of nintedanib with add-on pirfenidone is in keeping with the known profiles of the individual drugs in patients with IPF1 Exploratory efficacy analyses suggest a potential benefit of the combination treatment of...

Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments INGELHEIM, Germany & HØRSHOLM, Denmark -Thursday, September 7th 2017

(BUSINESS WIRE)-- Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of...

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH INGELHEIM, Germany & SYDNEY -Thursday, August 24th 2017

Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH) New study underscores Boehringer Ingelheim’s aspiration to deliver more...